Related Experiment Videos
The combination measles, mumps, rubella and varicella vaccine in healthy children
Insights
The combination measles, mumps, rubella, varicella vaccine (MMRV) and sequential measles, mumps, rubella (MMR) plus varicella (V) vaccines show similar immunogenicity and safety in young children. Both vaccination schedules effectively protect against these common childhood diseases.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Immunology
Background:
- Childhood immunization programs aim to prevent serious infectious diseases.
- The measles, mumps, rubella, varicella vaccine (MMRV) offers a combined approach to immunization.
- Assessing the efficacy and safety of combined vaccines is crucial for public health.
Purpose of the Study:
- To compare the immunogenicity and clinical reactivity of the combination MMRV vaccine versus sequential MMR + V vaccines.
- To evaluate antibody persistence and response to varicella exposure after vaccination.
- To determine the safety and cost-effectiveness of the MMRV vaccine in healthy children.
Main Methods:
- A clinical trial involving 15- to 17-month-old healthy children.
- Administration of either the MMRV vaccine or sequential MMR + V vaccines.
- Measurement of seroconversion rates, antibody titers, and clinical reactions post-immunization.
Main Results:
- Both MMRV and MMR + V schedules achieved nearly 100% seroconversion for all vaccine components.
- Similar mean antibody titers were observed between the two groups for each virus.
- Clinical reactivity, including rashes and fever, was comparable between the MMRV and MMR + V groups.
Conclusions:
- The combination MMRV vaccine is immunogenic and safe, comparable to the sequential MMR + V schedule.
- MMRV provides a safe, effective, and potentially cost-effective option for varicella immunization in children.
- Antibodies to measles, mumps, and rubella remained persistent post-vaccination in most recipients.
Abstract:
A clinical trial was conducted to compare the combination measles, mumps, rubella, varicella vaccine (MMRV) and the standard measles, mumps, rubella vaccine and subsequent varicella vaccine (MMR + V) in 15 to 17 month old healthy children. Both the MMRV and MMR + V schedules stimulated virtually 100% seroconversion for all component viruses. Mean antibody titers were similar for each virus component in the two vaccine groups. Clinical reactivity post immunization was also similar with 25-29% morbilliform rashes, 12-25% mild papulovesicular (varicella) rashes, and 12.5-18% temperature elevations above 101 degrees F. Antibodies to measles, mumps, and rubella viruses were persistent in 8/10 originally seronegative MMRV vaccinees and 5/5 MMR + V recipients tested. On MMRV recipient had a household exposure to chickenpox during the year postvaccination that resulted in a subclinical boost in varicella antibody titer. Two children in the MMR + V group had close varicella exposures: one developed mild varicella (20 lesions). There were no known exposures to natural measles, mumps, or rubella. Three of four MMRV vaccinees with low titer antibody to varicella prior to immunization had greater than four-fold rises in antibodies. The combination measles, mumps, rubella, varicella vaccine is an immunogenic, safe and cost effective approach to varicella immunization of healthy children.